Liquidia to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020

Rhea-AI Summary

Liquidia Technologies (Nasdaq: LQDA) announced plans to release its second quarter 2020 financial results on August 10, 2020. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and provide corporate updates. The company focuses on developing novel therapeutics using its proprietary PRINT® technology, primarily targeting pulmonary arterial hypertension (PAH) with its product candidate LIQ861 and local post-operative pain with LIQ865. Liquidia aims to improve patient outcomes through precise drug particle production.

Positive

• Forthcoming Q2 2020 financial results announcement and corporate update.
• Development of LIQ861 and LIQ865 for PAH and post-operative pain.

Negative

• None.

RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced that second quarter 2020 financial results will be reported on Monday, August 10, 2020. The company will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and provide a corporate update.

The live call may be accessed by dialing 1-877-707-8711 (domestic) or 1-857-270-6219 (international) and entering the conference code: 7295403. A live and archived webcast of the call will also be available on the Events & Presentations page of the Liquidia website.

About Liquidia

Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC. For more information, please visit www.liquidia.com.

Contact Information

Investors:
Jason Adair
Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com

Media:
Michael Parks
Corporate Communications
484.356.7105
michael.parks@liquidia.com

FAQ

What date will Liquidia Technologies report its Q2 2020 financial results?

Liquidia Technologies will report its Q2 2020 financial results on August 10, 2020.

What is the focus of Liquidia Technologies?

Liquidia Technologies is focused on developing novel biopharmaceutical products using its proprietary PRINT® technology.

Which product candidates is Liquidia developing?

Liquidia is developing LIQ861 for pulmonary arterial hypertension and LIQ865 for local post-operative pain.

What time is the Liquidia conference call scheduled?

The conference call is scheduled for 4:30 p.m. ET on August 10, 2020.

How can I access the Liquidia conference call?

You can access the call by dialing 1-877-707-8711 (domestic) or 1-857-270-6219 (international) and entering the code: 7295403.